scholarly journals Acute Effects of Dipyrone on Renal Function in Patients with Cirrhosis: A Randomized Controlled Trial

2014 ◽  
Vol 116 (3) ◽  
pp. 257-263 ◽  
Author(s):  
Pedro Zapater ◽  
Lucia Llanos ◽  
Claudia Barquero ◽  
Pablo Bellot ◽  
Sonia Pascual ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Renal Function ◽  
Controlled Trial ◽  
Acute Effects ◽  
Randomized Controlled

The role of mannitol in the protection of renal function during EVAR: a randomized controlled trial

2013 ◽  
Vol 30 ◽  
pp. 65-65
Author(s):  
A. Pandazi ◽  
K. Kalimeris ◽  
N. Nikolakopoulos ◽  
M. Riga ◽  
P. Matsota ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Renal Function ◽  
Controlled Trial ◽  
Randomized Controlled

scholarly journals Dexmedetomidine improved renal function in patients with severe sepsis: an exploratory analysis of a randomized controlled trial

2020 ◽  
Vol 8 (1) ◽  
Author(s):  
Tsuyoshi Nakashima ◽  
◽  
Kyohei Miyamoto ◽  
Nozomu Shima ◽  
Seiya Kato ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Renal Function ◽  
Severe Sepsis ◽  
Sofa Score ◽  
Controlled Trial ◽  
Mortality Rates ◽  
Apache Ii ◽  
Apache Ii Score ◽  
Randomized Controlled ◽  
Initial Comparison

Abstract Background Dexmedetomidine has been reported to improve organ dysfunction in critically ill patients. In a recent randomized controlled trial (Dexmedetomidine for Sepsis in Intensive Care Unit (ICU) Randomized Evolution [DESIRE]), we demonstrated that dexmedetomidine was associated with reduced mortality risk among patients with severe sepsis. We performed this exploratory sub-analysis to examine the mechanism underlying improved survival in patients sedated with dexmedetomidine. Methods The DESIRE trial compared a sedation strategy with and without dexmedetomidine among 201 mechanically ventilated adult patients with sepsis across eight ICUs in Japan. In the present study, we included 104 patients with Acute Physiology and Chronic Health Evaluation II (APACHE II) scores of ≥ 23 (54 in the dexmedetomidine [DEX] group and 50 in the non-dexmedetomidine [non-DEX] group). Initially, we compared the changes in the sequential organ failure assessment (SOFA) scores from the baseline within 6 days after randomization between groups. Subsequently, we evaluated the variables comprising the organ component of the SOFA score that showed relevant improvement in the initial comparison. Results The mean patient age was 71.0 ± 14.1 years. There was no difference in the median APACHE II score between the two groups (29 [interquartile range (IQR), 25–31] vs. 30 [IQR, 25–33]; p = 0.35). The median SOFA score at the baseline was lower in the DEX group (9 [IQR, 7–11] vs. 11 [IQR, 9–13]; p = 0.01). While the renal SOFA subscore at the baseline was similar for both groups, it significantly decreased in the DEX group on day 4 (p = 0.02). During the first 6 days, the urinary output was not significantly different (p = 0.09), but serum creatinine levels were significantly lower (p = 0.04) in the DEX group. The 28-day and in-hospital mortality rates were significantly lower in the DEX group (22% vs. 42%; p = 0.03, 28% vs. 52%; p = 0.01, respectively). Conclusion A sedation strategy with dexmedetomidine is associated with improved renal function and decrease mortality rates among patients with severe sepsis. Trial registration This trial was registered on ClinicalTrials.gov (NCT01760967) on January 1, 2013.

Sign in / Sign up

Export Citation Format

Share Document